The Motley Fool EN

Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Hims & Hers stock traded more than 40% higher after the deal was announced.

Mar 09, 2026 &03240909202631; 16:24 UTC www.fool.com Trending 3/5

Read original on www.fool.com ↗

↗

Positive for markets

Sentiment score: +75/100

High impact Short-term (days)

WHAT THIS MEANS

Hims & Hers Health shares surged over 40% following a strategic deal announcement with Novo Nordisk, a major pharmaceutical company. This partnership significantly validates the telehealth platform's business model and market position in the growing weight-loss and chronic disease management sector.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

HIMS

HIMSStock

Expected to rise

40%+ share price surge on Novo Nordisk partnership announcement, indicating strong market validation and revenue growth potential

↑

Novo Nordisk

NVOStock

Expected to rise

Novo Nordisk benefits from expanded distribution channel for GLP-1 drugs through Hims telehealth platform

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider taking profits on the 40% spike given the sharp move, but accumulate on any pullbacks for long-term exposure to the telehealth-pharma convergence trend. Monitor valuation metrics post-rally to assess if the stock remains attractively priced.

KEY SIGNALS

Major pharmaceutical partnership validates telehealth modelSignificant share price appreciation (40%+)Access to Novo Nordisk's weight-loss and diabetes medicationsRevenue diversification and growth catalystMarket consolidation in digital health space

SECTORS INVOLVED

HealthcareTelehealthPharmaceuticalsDigital Health

Analysis generated on Mar 10, 2026 at 01:08 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by The Motley Fool. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

RELATED INTELLIGENCE